Business
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou’s management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, at 12:30pm ET in New York, New York. For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Carib
About this update from Caribou Biosciences, Inc.
[{"type":"image","alt":"Caribou Biosciences, Inc.","displaySize":"","headline":null,"caption":"Caribou Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/daefc0c372fe0c4b67822f8b9179087c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Rnd4qeRJ_xjp9Qy6VyL25w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/daefc0c372fe0c4b67822f8b9179087c","width":300,"height":74},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Rnd4qeRJ_xjp9Qy6VyL25w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/daefc0c372fe0c4b67822f8b9179087c","width":300,"height":74}},"lazy":false},{"type":"text","content":"BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou’s management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, at 12:30pm ET in New York, New York.","length":368,"tagName":"p"},{"type":"text","content":"For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.","length":179,"tagName":"p"},{"type":"text","content":"About Caribou Biosciences, Inc.Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou’s chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the company @CaribouBio and visit www.cariboubio.com.","length":642,"tagName":"p"},{"type":"text","content":"Caribou Biosciences, Inc. contact:Peggy Vorwald, [email protected]@cariboubio.com","length":108,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]